New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
11:37 EDTEW, MDTMedtronic says jury awarded Edwards Lifesciences damages of $392.5M
A jury in the Federal District Court of Delaware today decided in favor of Edwards Lifesciences (EW), ruling that the Medtronic (MDT) CoreValve System infringed on Edward's Cribier patent. Medtronic intends to appeal. "While we are disappointed in the jury's verdict, we continue to believe that this decision will be overturned on appeal," said Neil Ayotte, vice president and acting general counsel at Medtronic. "Medtronic has prevailed against Edwards in several legal actions related to a European counterpart to this patent and others, and believes the Federal Circuit Court of Appeals will find no merit to Edward's infringement claim. Today's jury verdict does not impose an injunction, and Medtronic will oppose any requests for an injunction by Edwards." The jury found willful infringement and awarded Edwards total damages in the amount of $392.5M. Medtronic anticipates U.S. regulatory approval of the CoreValve System for extreme risk patients by the end of its FY14, and intends to begin selling the device in the U.S. at that time.
News For MDT;EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 11, 2014
09:05 EDTMDTMedtronic receives FDA approval for Attain Performa LV quadripolar leads
Subscribe for More Information
December 9, 2014
08:07 EDTEWEdwards Lifesciences price target raised to $155 from $135 at JMP Securities
Subscribe for More Information
07:36 EDTEWEdwards Lifesciences TAVI growth reinforces bullish stance, says Canaccord
Subscribe for More Information
07:07 EDTEWEdwards price target raised to $151-$152 from $135-$140 at Wells Fargo
Wells Fargo increased its price target on Edwards Lifesciences as the firm believes that the company's roughly in-line 2015 guidance announced yesterday is conservative.The firm also notes that the company raised its long-term TAVR market assumption to over $3B in 2019. The firm keeps an Outperform rating on the shares.
December 8, 2014
08:16 EDTEWEdwards Lifesciences announces investments in CardioKinetix
Edwards made a structured investment in CardioKinetix, a privately held medical device company pioneering a catheter-based treatment for heart failure. This transaction increases Edwards' existing minority interest in CardioKinetix and provides an option to purchase the remaining outstanding shares for a future payment, plus additional milestone payments based on future regulatory and reimbursement approvals. In the second investment, the company acquired intellectual property that broadens its transcatheter mitral valve development efforts. Additional details of both investments were not disclosed.
08:15 EDTEWEdwards Lifesciences sees FY15 EPS $3.90-$4.10, consensus $3.96
Subscribe for More Information
08:12 EDTEWEdwards Lifesciences backs FY14 EPS $3.33-$3.39, consensus $3.39
Subscribe for More Information
06:05 EDTEWEdwards Lifesciences to host investor meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use